Virus-Like Particle Vaccines
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they in...
I tiakina i:
| Hōputu: | Online |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Ngā marau: | |
| Urunga tuihono: | ONIX_20210501_9783039430741_832 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869517549201260544 |
|---|---|
| collection | Directory of Open Access Books |
| description | The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation. |
| format | Online |
| id | doab-20.500.12854ir-69086 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-690862024-04-01T23:19:19Z Virus-Like Particle Vaccines Bachmann, Martin F Vogel, Monique virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation. 2021-05-01T15:40:48Z 2021-05-01T15:40:48Z 2020 book ONIX_20210501_9783039430741_832 9783039430741 9783039430758 https://directory.doabooks.org/handle/20.500.12854/69086 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2855 https://mdpi.com/books/pdfview/book/2855 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03943-075-8 10.3390/books978-3-03943-075-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039430741 9783039430758 262 Basel, Switzerland open access |
| spellingShingle | virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues Virus-Like Particle Vaccines |
| title | Virus-Like Particle Vaccines |
| title_full | Virus-Like Particle Vaccines |
| title_fullStr | Virus-Like Particle Vaccines |
| title_full_unstemmed | Virus-Like Particle Vaccines |
| title_short | Virus-Like Particle Vaccines |
| title_sort | virus like particle vaccines |
| topic | virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues |
| topic_facet | virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues |
| url | ONIX_20210501_9783039430741_832 |